Miles Prince
@MilesPrince4
Followers
527
Following
286
Media
10
Statuses
296
Haematologist and blood cancer researcher. Passionate about Philanthropy through Snowdome Foundation, Maddie Riewoldt Vision, Epworth Foundation and PeterMac
Australia
Joined June 2017
Congratulations to Dr Josh Tobin @JwdTobin from @MaterResearch Institute-The University of Queensland on being awarded the Snowdome Foundation #Haematology Fellowship. Dr Tobin aims to improve outcomes for #follicularlymphoma patients. #QueenslandUniversity
1
3
10
It's World Blood Donor Day this Sunday, and Australians are being urged to donate to help buy more time for patients in need. #TDE7
0
2
4
Outstanding news today for myeloma patients: FDA approves subcutaneous Daratumumab, DARZALEX FASPRO (daratumumab & hyaluronidase-fihj). Fixed-dose injection given in 3 to 5 minutes. Convenient, safe, effective! #mmsm @theMMRF @IMFmyeloma
globenewswire.com
Company Announcement Subcutaneous formulation of daratumumab, DARZALEX FASPRO™, approved by the U.S. FDA for the treatment of patients with multiple...
6
41
132
Join me in stopping the spread of COVID-19! Download COVIDSafe, an app from the Australian Government. #COVID19
#coronavirusaustralia #stayhomesavelives
0
1
6
Pretty frustrating to see so much misunderstanding with the antimalarial drugs chloroquine and hydroxychloroquine (C/HC) as presented by politicians and the media. The nuances, which are critical, are lost. My short primer on this. The "skinny" on C/HQ 1/x #COVID19
14
85
180
I intubated my colleague today, a young, healthy ER doc like me. This is what I learned...
3K
33K
130K
WATCH 🎥 MRD in #myeloma: Can maintenance with lenalidomide increase MRD-negativity rates? The @MM_Hub spoke to @DrOlaLandgren at the #ASH19 meeting about the latest data from a phase II trial investigating lenalidomide as maintenance therapy: https://t.co/g6JoQgjdEr
#mmMRD
0
4
5
In 2020, we'll celebrate 100 years of care. As we celebrate our centenary, we'll reflect on our past, continue our commitment to care into the future & recognise you, our community, for helping us reach this milestone #Epworth100
0
2
6
🎥 @StefanoLuminari from @UNIMORE_univ discusses the need for use of geriatric assessment tools to guide treatment decisions for elderly patients with DLBCL and comments on such tools presented during ASH 2019. Also available in Italian. https://t.co/z2x4ivECyF
#ASH19 #lymsm
0
6
10
CONGRESS | #IMW2019 | @DrOlaLandgren presents results of a phase 1b study of once-weekly carfilzomib plus Rd (KRd) in patients with NDMM. KRd (56mg/m^2) feasible and active: response rates comparable to twice weekly dosing in frontline setting. Further evaluations required #mmsm
0
8
11
CONGRESS | #SOHO2019 | @DrJulieVose from @UNMC talks about new frontline regimens in T-cell lymphoma. #lymsm @lymphomahub
1
4
9
Amgen Announces Phase 3 CANDOR Study Combining KYPROLIS® (carfilzomib) And DARZALEX® (daratumumab) Meets Primary Endpoint Of Progression-Free Survival | BioSpace
biospace.com
Amgen (NASDAQ:AMGN) today announced the Phase 3 CANDOR study evaluating KYPROLIS® (carfilzomib) in combination with dexamethasone and DARZALEX® (daratumumab) (KdD) compared to KYPROLIS and dexameth...
0
0
1
Even as recently as the 1960s, the five-year survival rate for leukemia was 14%. By 2010, it had increased to 61%.
biospace.com
Blood cancer is actually a term applied to three different types of cancer – leukemia, lymphoma, and myeloma. For centuries, these cancers had virtually no possibility of survival. Even as recently...
0
2
5
Congratulations @MM_Hub and @sci_ed_support team 🥳👍🏻👌🏻👍🏻
Back for day 3 of #IMW2019 and delighted that we now have more than 2000 followers! 👏🏻 We are passionate about making the latest data in myeloma available, so we will continue bringing you extensive coverage from the key sessions at IMW 2019! Welcome new followers! #mmsm
0
1
4
CONGRESS | #IMW2019 | A pleasure to be welcomed by Boston Mayor @marty_walsh. He spoke about the importance of cancer research and care, and his own experience of having Burkitt lymphoma as a child #mmsm
0
2
3